Attention deficit hyperactivity disorder (ADHD) - methylphenidate (replaced by TA98)
Methylphenidate, atomoxetine and dexamfetamine for the treatment of attention deficit hyperactivity disorder in children and adolescents (including a review of TA13)
| Guidance type:
Technology appraisal
|
| Date issued:
October 2000
|
| Guidance currently being reviewed:
See review |
| Reference:
TA13 |
Documents
For healthcare professionals
For patients, carers and the public
Background information
|
Implementing this guidance
Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
